Lenacapavir is a twice-yearly injectable medication designed to be used as pre-exposure prophylaxis (PrEP). The FDA is giving ...

The Food and Drug Administration (FDA) has accepted under Priority Review the New Drug Application (NDA) for lenacapavir, a long-acting HIV-1 capsid inhibitor, for the prevention of HIV as ...

The US Food and Drug Administration (FDA) has accepted Gilead’s new drug application (NDA) for lenacapavir and set a prescription drug user fee act (PDUFA) target action date of ...

By paralyzing frontline response efforts led by community groups, the US decision to freeze funding is weakening health systems across the Global South. The freeze not only jeopardizes precious gains ...

The FDA has accepted Gilead Sciences’ new drug application for lenacapavir as a long-lasting injectable to prevent HIV ...

Despite breakthroughs in HIV treatment and prevention worldwide, critical challenges such as stigma, unequal access and ...

With treatment, people living with HIV can have long and healthy lives. However, if left untreated, it can cause a weakened immune system or acquired immune deficiency syndrome (AIDS). Some people may ...

Observational studies are critical tools in clinical research and public health response, but challenges arise in ensuring ...

In 1980, when Dr. Paul Benson opened his LGBTQ-affirming Be Well Medical Center in Berkley, advertising featuring LGBTQ+ ...

“It’s bad, bad,” said one State Department official who works on the HIV program, which is called the President’s Emergency Plan for AIDS Relief, or PEPFAR. The official, who, like ...

In observance of Black HIV/AIDS Awareness Day, we are called to reflect on the ongoing epidemic and its disproportionate ...